RxDoctor Payments Data

Jennifer Smith, MD

Internal Medicine · Mechanicsville, VANPI 1972574770

Payments from drug & device makers

$706in general payments, 2019–2025

Across 39 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$278
  • Abbott$213
  • Dexcom, Inc.$64
  • Johnson & Johnson$35
  • Amarin Pharma, Inc.$30
  • Boehringer Ingelheim$19
  • plus $68 from 5 others

What the payments were for

  • Food & beverage$68797%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$706 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$114,643
Medicare patients
558
Services billed
1,910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$216,776
TrulicityDulaglutide84$124,313
JanuviaSitagliptin Phosphate75$94,591
EliquisApixaban100$92,604
MounjaroTirzepatide57$66,989
JardianceEmpagliflozin41$55,190
FarxigaDapagliflozin Propanediol14$22,861
XareltoRivaroxaban16$15,934
TradjentaLinagliptin15$14,996
Breo ElliptaFluticasone/Vilanterol19$14,302
MyrbetriqMirabegron17$13,200
Lantus SolostarInsulin Glargine,hum.Rec.Anlog103$11,482
Atorvastatin Calcium743$5,963
Rosuvastatin Calcium501$5,286
Losartan Potassium500$4,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$216,776148 claims
Boehringer IngelheimJardiance, Tradjenta$19$70,18656 claims
Johnson & JohnsonXarelto$35$15,93416 claims
GSKBreo Ellipta$15$14,30219 claims
AbbVieSynthroid$278$2,83397 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →